AnodyneWiki

Ibogaine

Ibogaine
Ibogaine
Salts
[]
Ibogaine hydrochloride
Ibogaine hydrochloride
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass310.40 g/mol [1]
Melting point148 °C [1]
SolubilitySoluble in chloroform [1]
Predicted LogP3.9 [1]
Structural Identifiers
[]
Molecular formulaC20H26N2O
IUPAC name(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene
SMILESCC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC
InChIInChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1
InChIKeyHSIBGVUMFOSJPD-CFDPKNGZSA-N
CAS number83-74-9
UNII3S814I130U
PubChem CID197060
Pharmacokinetics[]
Onset1–3 hours
Elimination half-lifeIbogaine: 7 hours, Noribogaine: 24–50 hours
Duration of action18–36 hours (but up–96 hours or more in total)
Routes of administrationOral[3]
Toxicity
[]
Mouse:
- intragastric: 263 mg/kg
 [1]

Ibogaine (also known as Endabuse, (-)-Ibogaine, Nih 10567, 12 Methoxyibogamine, Nih10567, 201-498-4, 12-Methoxyibogamine, Ibogain, (5β)-12-methoxyibogamine or Tabernanthe iboga) is a psychedelic substance of the hexahydroazepinoindole and tryptamine class.

Chemistry

Salts []

Ibogaine is typically found in the form of its hydrochloride salt.

 []

Ibogaine is a single defined stereoisomer.

Ibogaine matches Lipinski's rule of five.

There are currently 3 reagent-interactions on

ReagentColor changeDescription
Marquispurplish > brown > orange
Ehrlichpurplish
Hofmannyellow / green

Pharmacology

Mechanism of action []

... In this study, /researchers/ first characterized the actions of ibogaine on ethanol self-administration in rodents. Ibogaine decreased ethanol intake by rats in two-bottle choice and operant self-administration paradigms. Ibogaine also reduced operant self-administration of ethanol in a relapse model. Next, /the researchers/ identified a molecular mechanism that mediates the desirable activities of ibogaine on ethanol intake. Microinjection of ibogaine into the ventral tegmental area (VTA), but not the substantia nigra, reduced self-administration of ethanol, and systemic administration of ibogaine increased the expression of glial cell line-derived neurotrophic factor (GDNF) in a midbrain region that includes the VTA. In dopaminergic neuron-like SHSY5Y cells, ibogaine treatment upregulated the GDNF pathway as indicated by increases in phosphorylation of the GDNF receptor, Ret, and the downstream kinase, ERK1 (extracellular signal-regulated kinase 1). Finally, the ibogaine-mediated decrease in ethanol self-administration was mimicked by intra-VTA microinjection of GDNF and was reduced by intra-VTA delivery of anti-GDNF neutralizing antibodies. Together, these results suggest that GDNF in the VTA mediates the action of ibogaine on ethanol consumption. These findings highlight the importance of GDNF as a new target for drug development for alcoholism that may mimic the effect of ibogaine against alcohol consumption but avoid the negative side effects. [1]

Experience reports

Erowid

There are currently 30 experience reports involving ibogaine on : []

Reddit

There are currently 6 trip reports involving ibogaine on : []

 []

  • Australia: Ibogaine is a legal.
  • Canada: Ibogaine is a legal.[4]
  • New Zealand: Ibogaine is Prescription only.[5]
  • United Kingdom: Ibogaine is a PSA.
  • United Nations: Ibogaine is Unscheduled.
  • United States: Ibogaine is a Schedule I under the "Controlled Substances Act".

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 197060, Ibogaine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/197060
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Ibogaine. UNII: 3S814I130U. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/3S814I130U
  3. Ballentine G, Friedman SF, Bzdok D. Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences. Science Advances. March 2022; 8(11). PMID 35294242. https://doi.org/10.1126/sciadv.abl6989
  4. Notice - Prescription Drug List (PDL): Multiple additions. Health Canada. 12 May 2017. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-2017-05-16-eng.php
  5. Galea S, Lorusso M, Newcombe D, Walters C, Williman J, Wheeler A. Ibogaine—be informed before you promote or prescribe. Journal of Primary Health Care. March 2011; 3(1):86–87. PMID 21359272. https://www.rnzcgp.org.nz/assets/documents/Publications/JPHC/March-2011/JPHCMarch11CompleteIssue.pdf#page=86

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 03:07:01
drugsprook2026-11-20 03:06:57
erowidok2026-11-20 03:07:05
gsrsok2026-11-20 03:06:57
hmdbmissing (no HMDB id)2026-11-20 03:06:57
keggmissing (no KEGG DRUG entry)2026-11-20 03:07:00
pubchemok2026-11-20 03:06:56
redditok2026-11-20 03:06:57
sidermissing (not in SIDER)2026-11-20 03:06:57
structureok2026-11-20 03:06:57
wikipediaok2026-11-20 03:06:57